High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Condition:   Hypercholesterolemia
Interventions:   Drug: Placebo;   Drug: Ezetimibe 10 mg;   Drug: Atorvastatin 10 mg;   Drug: Atorvastatin 20 mg;   Drug: Atorvastatin 40 mg;   Drug: Atorvastatin 80 mg
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: Evinacumab;   Drug: Matching placebo;   Other: Background Lipid Modifying Therapy (LMT)
Sponsor:   Regeneron Pharmaceuticals
Recruiting

Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)

Condition:   Familial Hypercholesterolemia
Interventions:   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Ezetimibe;   Drug: Placebo for Ezetimibe
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Clinical Decision Support for Familial Hypercholesterolemia

Conditions:   Hypercholesterolemia, Familial;   Clinical Decision Support
Intervention:   Other: Clinical decision support
Sponsor:   University Hospital, Linkoeping
Not yet recruiting

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

Condition:   Hypercholesterolemia
Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Fluvastatin;   Drug: Pravastatin;   Drug: Lovastatin
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Condition:   Hypercholesterolaemia
Interventions:   Drug: Alirocumab SAR236553 (REGN727);   Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Simvastatin;   Drug: Pravastatin;   Drug: Lovastatin;   Drug: Fluvastatin;   Drug: Ezetimibe;   Drug: Cholestyramine;   Drug: Nicotinic acid;   Drug: Fenofibrate;   Drug: Omega-3 fatty acids;   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting

A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)

Condition:   Primary Hypercholesterolemia
Interventions:   Drug: Ezetimibe;   Drug: Placebo;   Drug: Simivastatin;   Drug: Statin
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

Condition:   Hyperlipidemia
Interventions:   Biological: Evolocumab;   Drug: Placebo
Sponsor:   Amgen
Completed

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Condition:   Homozygous Familial Hypercholesterolemia
Interventions:   Drug: Alirocumab;   Drug: Placebo
Sponsors:   Regeneron Pharmaceuticals;   Sanofi
Recruiting

Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)

Condition:   Hypercholesterolemia
Interventions:   Drug: Ezetimibe;   Drug: Atovastatin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Condition:   Hypercholesterolemia
Interventions:   Drug: Atorvastatin;   Drug: Ezetimibe;   Drug: Placebo for Ezetimibe;   Drug: Placebo for Atorvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Condition:   Hyperlipidemia
Interventions:   Biological: Evolocumab;   Drug: Ezetimibe;   Drug: Placebo to Evolocumab;   Drug: Placebo to Ezetimibe;   Drug: Atorvastatin;   Drug: Rosuvastatin;   Drug: Simvastatin
Sponsor:   Amgen
Completed

Chart Review of Repatha® in Subjects With Hyperlipidaemia

Condition:   Hypercholesterolaemia
Intervention:  
Sponsor:   Amgen
Recruiting

An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol

Conditions:   Atherosclerotic Cardiovascular Disease;   Symptomatic Atherosclerosis;   Type2 Diabetes;   Familial Hypercholesterolemia
Interventions:   Drug: Inclisiran;   Drug: Evolocumab
Sponsor:   The Medicines Company
Active, not recruiting

Effects of Atorvastatin in Graves' Orbitopathy (GO)

Conditions:   Thyroid Associated Ophthalmopathy;   Hypercholesterolemia
Interventions:   Drug: Atorvastatin;   Drug: Methylprednisolone
Sponsor:   University of Pisa
Not yet recruiting

Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

Condition:   Hypercholesterolemia
Interventions:   Combination Product: EZ 10 mg/Ator 10 mg;   Combination Product: EZ 10 mg/Ator 20 mg;   Drug: Atorvastatin;   Drug: Placebo for FDC EZ/Ator;   Drug: Placebo for atorvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Condition:   Hyperlipidemia
Interventions:   Biological: Evolocumab;   Drug: Placebo to Evolocumab;   Drug: Ezetimibe;   Drug: Placebo to Ezetimibe
Sponsor:   Amgen
Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Condition:   Hyperlipidemia
Interventions:   Biological: Evolocumab;   Drug: Ezetimibe;   Biological: Placebo to Evolocumab;   Other: Placebo to Ezetimibe
Sponsor:   Amgen
Completed

Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects)

Condition:   Lysosomal Acid Lipase Deficiency
Intervention:   Other: Observational study
Sponsor:   Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
Recruiting

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

Conditions:   Erectile Dysfunction, CTCAE;   Impotence;   Prostate Adenocarcinoma
Interventions:   Drug: Atorvastatin;   Drug: Pentoxifylline;   Dietary Supplement: Vitamin E Compound
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Conditions:   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Estrogen Receptor Negative;   HER2/Neu Negative;   Inflammatory Breast Carcinoma;   Progesterone Receptor Negative;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
Interventions:   Drug: Atorvastatin;   Drug: Capecitabine
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting

Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E

Condition:   Fatty Liver
Interventions:   Drug: Vitamin E 200 IU/d;   Drug: Vitamin E 400 IU/d;   Drug: Vitamin E 800 IU/d;   Behavioral: Diet and Exercise
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting

Efficacy of Probiotic Milk Formula on Blood Lipid and Intestinal Function

Condition:   Healthy
Intervention:   Combination Product: Probiotic Milk Formula
Sponsor:   Chung Shan Medical University
Completed

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

Condition:   Hyperlipidemia and Mixed Dyslipidemia
Interventions:   Biological: Evolocumab;   Drug: Standard of Care
Sponsor:   Amgen
Completed

The VA Diabetes Trial Follow-up Study (VADT-FS)

Conditions:   Diabetes;   Glycemic Control
Intervention:  
Sponsor:   VA Office of Research and Development
Completed

Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

Conditions:   Cancer;   Skin Fibroblasts;   Muscle Weakness
Intervention:   Dietary Supplement: Niagen
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting

A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

Economic Crisis and Adherence to the Mediterranean Diet (CASSIOPEA)

Conditions:   Dietary Habits;   Inflammation;   Economic Problems;   Obesity;   Diabetes;   Hypertension
Intervention:  
Sponsor:   Neuromed IRCCS
Recruiting

Improving Mental Health Through Integration With Primary Care in Rural Karnataka

Conditions:   Chronic Disease;   Depression;   Anxiety
Intervention:   Behavioral: Healthy Living Intervention
Sponsors:   University of California, San Francisco;   National Institute of Mental Health (NIMH)
Active, not recruiting